Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial.

J Headache Pain · 2015 · PMC4393401 · PMID 25916335

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Conclusions Treatment with a proprietary supplement containing magnesium, riboflavin and Q10 (Migravent® in Germany, Dolovent® in USA) had an impact on migraine frequency which showed a trend towards statistical significance.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The fact that the 200 mg topiramate arm in the MIGR-003 study did not reach statistical significance even with 143 patients (probably due to many early drop-outs) suggests that 55 patients are simply not enough to show statistical significance of any treatment in reducing migraine days.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.